当前位置:首页 > 关于我们 > 创投导师 > 衷兴华

衷兴华 | Zhong Xinghua




衷兴华


肝胆外科医生   曾任中国某三甲医院业务院长。

曾在法国Poitiers 大学学习管理,并在法国POITIERS大学医院担任院长助理(实习),学习法国的医院管理,研究了西方医疗保障体系。

曾在中国华源集团工作并担任过医药企业高管,积累了企业管理经验。

曾投资过多个中国TOP级别医药公司,积累了产业投资经验,。

衷兴华医生长期追踪研究肿瘤医疗新技术和新进展,曾参加过上海质子重粒子放疗中心(中国首个)项目论证工作,实地考察过全球主要的粒子放疗中心。

作为医疗专业委员,衷兴华担任中核集团同辐医疗投资基金独立委员。曾帮助著名投资基金鼎晖投资(CDH)和远大医药集团并购SIRTEX公司,首次把钇90核素治疗肝癌技术引进到中国。

 衷兴华医生现专注于肿瘤微创治疗等相关新技术研发,试图用工程化的手段创新肿瘤解决方案,并致力于推动:“局部治疗+化疗和免疫”治疗恶性肿瘤的系统化解决方案创新,以帮助更多癌症患者得到更好的治疗和帮助。


Zhong Xinghua is a hepatobiliary surgeon who previously served as the president of a major tertiary hospital in China.

He studied management at the University of Poitiers in France and served as Assistant to the Hospital Director (internship) at Poitiers University Hospital, where he gained in-depth knowledge of French hospital management and the Western healthcare security system.

He has also worked at China Huayuan Group and held senior executive positions in pharmaceutical companies, accumulating extensive experience in corporate management. In addition, he has invested in multiple top-tier pharmaceutical companies in China, building significant expertise in healthcare industry investment.

Dr. Zhong has long tracked and studied new technologies and advances in oncology. He participated in the feasibility study for the Shanghai Proton and Heavy Ion Radiotherapy Center — China’s first such facility — and conducted on-site visits to major particle therapy centers around the world.

As a medical expert committee member, Dr. Zhong serves as an Independent Director of the CNNC Tongfu Medical Investment Fund. He previously assisted the renowned private equity firm CDH Investments and Yuanda Pharmaceutical Group in the acquisition of Sirtex Medical, successfully introducing Yttrium-90 microsphere therapy for liver cancer to China for the first time.

Dr. Zhong now focuses on the research and development of new technologies in minimally invasive tumor treatment. He is committed to innovating tumor solutions through an engineering-driven approach and is dedicated to advancing systematic treatment innovations that combine local therapy with chemotherapy and immunotherapy for malignant tumors, with the goal of delivering better outcomes for more cancer patients.


0.154305s